Dr. Kass on Testing for HER2-Positive Breast Cancer

Fred C. Kass, MD
Published: Monday, Jul 20, 2015



Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Kass explains that fluorescence in situ hybridization (FISH) is preferred in the oncology community versus immunohistochemistry (IHC)upfront. IHC is only used first, he adds, when the FISH results are unequivocal. If both FISH and IHC results are equivocal, then oncologists send specimens to a reference lab.

Oncologists concur that testing patients with FISH first is more reliable method, Kass says.



Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Kass explains that fluorescence in situ hybridization (FISH) is preferred in the oncology community versus immunohistochemistry (IHC)upfront. IHC is only used first, he adds, when the FISH results are unequivocal. If both FISH and IHC results are equivocal, then oncologists send specimens to a reference lab.

Oncologists concur that testing patients with FISH first is more reliable method, Kass says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x